New Treatment Paradigms in CRPC: Enhancing Care through Emerging Diagnostics and Novel Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to June 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Genomic Health and Sanofi Genzyme

Description:
Prostate cancer remains the second leading cause of cancer deaths among American men. These deaths are typically the result of castration-resistant prostate cancer (CRPC), which occurs when patients' disease progresses despite castrate levels of testosterone. The treatment of CRPC has dramatically changed over the past decade. For many years, cytotoxic chemotherapy with docetaxel was the common form of treatment for patients with symptomatic or rapidly progressing disease. Since the approval of docetaxel, five additional therapeutic agents showing a survival benefit have been approved by the FDA in clinical trials. These include enzalutamide and abiraterone acetate, two agents designed specifically to affect the androgen axis; sipuleucel-T, which stimulates the immune system; cabazitaxel, a chemotherapeutic agent; alpharadin (or radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent; and the new generation antiandrogen agent enzalutamide.

Another recent success in CRPC is the improvement of understanding biologics and molecular drivers of prostate cancer growth and progression. These advances in the past few years have resulted in the investigations of several novel targeted therapies, including androgen receptor (AR) targeting agents, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors and proteasome inhibitors. Several of these drugs have either received approval from the FDA or have late stage development based on improvement of intermediate surrogate endpoints such as PSA levels or circulating tumor cell (CTC) counts in recent clinical trials. 

Upon completion of this activity, participants will be able to:

  • Analyze current and emerging agents and their mechanism of action in the management of castration-resistant prostate cancer (CRPC)

  • Examine available evidence in relation to current and advanced diagnostic methods for early detection in CRPC to help determine a more accurate assessment of risk

  • Explore recent evidence in terms of treatment sequencing in patients with metastatic prostate cancer

  • Discuss overview of available first-line treatments that represent standard of care in patients with metastatic castrate-resistant prostate cancer (mCRPC)

  • Assess the potential role of genomic testing and prognostic biomarkers to establish individualized treatment plan for patients with CRPC
     

Faculty: Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center

Disclosure:

Dr. Petrylak serves as a consultant for Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myer Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, and Urogen. He has received grant/research support from Ada Cap, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myer Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, and Urogen. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Genomic Health and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue